The potential of the LAMELLASOME™ Nucleic Acid Platform to assist in the transfer of a broad range of genetic material is demonstrated by two lead products:
LAMELLASOME™ CF-NA is a LAMELLASOME/plasmid treatment targeted at functional CFTR replacement therapy for Cystic Fibrosis. Lamellar has data to prove that LAMELLASOME CF-NA provides safe and effective delivery of functional plasmid to lungs in vivo, while avoiding gene therapy-associated immune response.
LAMELLASOME IPF-NA is a LAMELLASOME™/microRNA product that is being developed for the treatment of idiopathic pulmonary fibrosis.
Lamellar has shown that the miR is safely and effectively delivered by LAMELLASOME and that it has a significant downstream antifibrotic effect, demonstrated as a marked reduction in IPF biomarkers. All transfected cells demonstrated high transfection, high cell viability and maintenance of cell phenotype.
As well as LAMELLASOME Nucleic Acid Transfer technology, Lamellar is involved in other areas of research investigating the capabilities of the Company’s proprietary LAMELLASOME technology. These other research programs include anti-fibrotic, anti-infective, and drug delivery products.